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This experiment was designed to determine whether any hemodynamic benefits attend administration 
of equal pharmacologic doses of glucagon (1 &kg/m) by continuous intravenous infusion (Group I, 
n = 6) versus selective intraarterial infusion (Group II, n = 6) via the superior mesenteric artery 
(SMA) in dogs. Cardiac output, heart rate, mean arterial pressure, total peripheral resistance, 
pulmonary vascular resistance, superior mesenteric artery flow (SMAQ), SMA vascular resistance, and 
portal venous pressure were measured at baseline (BL) and at 5, 15, 30, and 45 min during glucagon 
infusion. SMAQ virtually doubled at 5 min from a baseline of 570 + 60 ml/min to 1158 + 146 
ml/min in Group I (P < O.OOl), and from a baseline of 527 + 17 1 to 1018 + 331 ml/min in Group 
II (P < 0.002). SMAQ was significantly higher in Group 1 at 30 and 45 min compared to Group II 
(P c 0.03) despite similar peripheral plasma glucagon levels. SMA vascular resistance was significantly 
lowered in both groups, with a greater reduction occurring during intravenous glucagon administration 
at 45 min (P < 0.05). Changes in systemic hemodynamic parameters, as well as glucagon and glucose 
levels were not statistically different between Groups I and II at any time period. Glucagon is a potent 
mesenteric vasodilator and the resultant profound splanchnic hemodynamic effects are as marked 
during intravenous administration as during selective SMA infusion. o 1985 Academic press, hc. 
The potential usefulness of mesenteric va- 
sodilators in treating acute mesenteric isch- 
emia became apparent from earlier reports 
of the efficacy of an aggressive therapeutic 
approach that included the adjunctive use of 
intraarterial papaverine [ 3 1. Unfortunately, 
papaverine may not be a very potent mes- 
enteric vasodilator [ 1, 111, and this agent 
may be ineffective when the superior mes- 
enteric artery (SMA) becomes occluded prox- 
imal to collateral vessels [ 16, 191. Further- 
more, intraarterial papaverine has been re- 
ported to have a deleterious effect on oxygen 
consumption in an animal model of acute 
mesenteric &hernia [ 141. Such disadvantages 
and the requirement that papaverine must 
be administered intraarterially in order to be 
effective, have led to studies of other potential 
splanchnic arterial vasodilators. Included 
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among such agents has been glucagon which 
has been shown to improve survival in a 
rodent model of acute mesenteric ischemia 
involving temporary complete SMA occlu- 
sion [lo]. 
Previous studies have verified that glucagon 
administered intravenously increases SMA 
flow out of proportion to the increase in 
cardiac output induced by this agent [9, 181. 
Furthermore, we have documented that this 
increase in SMA flow is of a nonshunt, 
nutritive nature [9], in contrast to previous 
speculation that increases in SMA flow re- 
sulted from increased arteriovenous shunting 
[7, 8, 211. The current work, representing an 
extension of earlier studies from our labora- 
tory, assessed the comparative splanchnic 
hemodynamic effects of equal pharmacologic 
doses of glucagon administered by selective 
intraarterial infusion compared with those 
effects following parenteral intravenous in- 
fusion. Data from this study might have an 
impact on future clinical trials evaluating 
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glucagon as a possible therapeutic agent for 
treating acute mesenteric &hernia. 
MATERIALS AND METHODS 
Twelve healthy adult dogs, weighing 22 to 
35 kg, were anesthetized using intravenous 
pentobarbital (30 mg/kg) with supplemental 
doses (5 mg/kg) administered as needed dur- 
ing preparation of the subjects. No experi- 
mental manipulations or measurements were 
performed until a stable hemodynamic base- 
line was attained 30 to 40 min after either 
initial or supplemental doses of pentobarbital 
were administered [ 121. Additional pentobar- 
bital was not administered after this baseline 
was achieved. Dogs were intubated and me- 
chanically ventilated in order to maintain 
physiologic arterial blood gases and normal 
blood pH (7.34-7.44). An esophageal probe 
monitored core temperature which was 
maintained with the use of an external heat 
source in all animals. Lactated Ringer’s so- 
lution was infused at a rate of 25 ml/kg/hr 
during the course of the experiment. A carotid 
arterial catheter, a jugular central venous 
catheter, and a 7 French thermodilution 
Swan-Ganz catheter were properly posi- 
tioned. After midline laparotomy, the supe- 
rior mesenteric artery was exposed and a 
carefully precalibrated, nonoccluding electro- 
magnetic flow probe was placed about its 
origin and appropriately zeroed for each sub- 
ject. A 21-gauge polyethylene catheter for 
intraarterial glucagon administration was in- 
serted into one of the mesenteric branches, 
and threaded into the SMA approximately 1 
to 2 cm from its origin, proximal to all 
branches. An 1 &gauge polyethylene catheter 
was threaded into the portal vein through a 
pancreaticoduodenal venous branch. The ab- 
dominal viscera were returned to the perito- 
neal cavity, and the abdominal incision 
was reapproximated prior to hemodynamic 
testing. 
Central venous, pulmonary artery, carotid 
arterial, and portal venous pressures were 
continuously recorded using pressure trans- 
ducers connected to a multichannel recorder. 
Cardiac output was measured by thermo- 
dilution. SMA flow was measured using a 
square wave flowmeter and was continuously 
recorded. Heart rate and pulmonary capillary 
wedge pressure were determined, and blood 
samples were withdrawn through the central 
venous catheter for venous glucose and glu- 
cagon level measurements. Plasma glucose 
was determined by a standard automated 
hexokinase method. Plasma glucagon was 
determined by radioimmunoassay [20]. 
Cardiac output (CO-liter/m), mean ar- 
terial pressure (MAP-mm Hg), central ve- 
nous pressure (CVP-mm Hg), mean pul- 
monary artery pressure (PAP-mm Hg), pul- 
monary vascular resistance (PVR = MPAP 
- PCWP/CO X 79.9-dynes-sec/cm5), total 
peripheral resistance (TPR = MAP - CVP/ 
CO X 79.9-dynes-sec/cm$ SMA blood flow 
(SMAQ-ml/m), portal venous pressure 
(PVP-mm Hg), SMA resistance (SMAR 
= MAP - PVP/SMAQ (liter/m) X 79.9- 
dynes-sec/cm5), and an estimate of left 
ventricular stroke work [LVSW = (MAP 
- PCWP) X CO/HR] were measured or cal- 
culated in the usual fashion at baseline (BL) 
and at 5, 15, 30, and 45 min during infusion 
of 1 pg/kg/m glucagon in a 45-ml volume of 
normal saline using a calibrated Harvard 
infusion pump. Infusions were administered 
through either a peripheral vein in six dogs 
(Group I) or directly into the SMA in six 
additional dogs (Group II). Data were sub- 
jected to statistical analysis using the Univer- 
sity of Michigan MIDAS statistical program. 
The paired t test was used for evaluation of 
differences within a Group, with the unpaired 
t test and Mann-Whitney U median tests 
were used for assessing differences between 
Groups I and II. Creation of correlation 
matrices with calculation of the Pearson 
product-moment correlation coefficients were 
also used in the statistical analyses. 
RESULTS 
None of the baseline parameters measured 
in this study were significantly different be- 
tween Group I receiving glucagon intrave- 
232 JOURNAL OF SURGICAL RESEARCH: VOL. 39, NO. 3. SEPTEMBER 1985 
nously compared to Group II receiving glu- 
cagon intraarterially. 
During glucagon infusion CO did not differ 
between the two groups (Table l), although 
changes within each group did occur. CO 
was increased significantly in both Groups at 
5 min (P < 0.03), but subsequently was not 
significantly different from control values. 
Left ventricular stroke work was decreased 
by 15 min in both groups (P < 0.02), and 
subsequently remained lower than baseline 
values. Heart rate significantly increased 
throughout the infusions of glucagon regard- 
less of the route of administration (P < 0.005). 
The degree of tachycardia was not different 
between the groups at any time period. 
Mean arterial pressure decreased signifi- 
cantly following 15 min of intravenous in- 
fusion (P < 0.02), and remained below the 
baseline of 133 mm Hg, reaching 110 mm 
Hg at 45 min. Mean arterial pressure follow- 
ing intraarterial administration was also di- 
minished at 15 min (P < O.Ol), and likewise 
remained lower than control values for the 
remainder of the infusion, dropping from a 
baseline of 129 to 105 mm Hg at 45 min. 
TPR decreased significantly throughout 
intravenous glucagon administration in 
Group I (P < 0.04). Total peripheral vascular 
resistance decreased at 5 min in Group II 
and remained lower than control values at 
45 min in the group receiving glucagon in- 
traarterially (P < 0.03). Differences in TPR 
between the two groups never attained sig- 
nificance. There was no significant change in 
mean pulmonary artery pressure, or pulmo- 
nary vascular resistance within or between 
the groups. 
Mesenteric hemodynamics were markedly 
altered in both groups (Table 2). Intrave- 
nously administered glucagon doubled SMA 
blood flow from a baseline of 570 f 60 ml/ 
mto1158f 146ml/mby5min(P~0.001). 
This increase in SMAQ persisted throughout 
intravenous drug infusion. Similarly, intraar- 
terial glucagon nearly doubled SMA flow (P 
< 0.002), but there appeared to be a less 
sustained response to glucagon in this group 
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SMAQ was significantly greater in dogs re- 
ceiving glucagon intravenously compared to 
those receiving the drug intraarterially 
(P < 0.03) and the difference in SMAQ be- 
tween groups already approached significance 
as early as 15 min (0.05 < P < 0.10). Reduc- 
tions of SMAR were present in both groups 
throughout glucagon infusion (P -c 0.01). 
SMAR was significantly lower at 45 min in 
the dogs receiving glucagon intravenously (P 
-C 0.05) compared with those receiving in- 
traarterial glucagon. 
The rise in portal venous pressure, thought 
to reflect increased SMAQ [9, 1 I], not nec- 
essarily arteriovenous shunting, was higher 
than control values (P < 0.03) in Group I, 
and was also higher than controls during 
intraarterial administration in Group II until 
45 min when the values were not different 
from controls. 
Glucose levels were elevated above control 
values throughout the study within both 
groups, but there was no difference in the 
degree of hyperglycemia achieved between 
the two groups (Table 3). Despite the minor 
differences in splanchnic hemodynamics be- 
tween the two groups, no difference in blood 
glucagon levels occurred between the two 
methods of glucagon administration at the 
dosage level used in this study. Within each 
group over the course of study, glucagon 
levels correlated directly with SMAQ, PVP, 
HR, and glucose levels and inversely with 
TPR, SMAR, and LVSW (P < 0.05). 
The purpose of this experiment was to 
assess the splanchnic vasoactive effects of 
glucagon administered intravenously com- 
pared to direct intraarterial SMA administra- 
tion. Others have suggested that intraarterial 
administration of glucagon may provide a 
beneficial vasodilatory effect in the manage- 
ment of nonocclusive mesenteric ischemia 
[6, 22, 241. Data from the present canine 
study supports the conclusion that intrave- 
nous glucagon in pharmacologic doses is as 
effective in increasing total SMA flow and 











reducing splanchnic vascular resistance as is 
selectively administered glucagon. If one were 
to use glucagon as an adjunct in the clinical 
treatment of acute mesenteric ischemia, there 
might be no advantage to infusion of glucagon 
directly into the SMA compared with simple 
parenteral intravenous administration. Fur- 
ther, the potentially deleterious side effects 
of hyperglycemia and tachycardia resulting 
from intravenous glucagon administration 
were equally evident in this study during 
intraarterial infusion. 
The rationale for the use of vasodilators 
in treating mesenteric ischemia relates pri- 
marily to the presence of reversible vaso- 
spasm. Lauffman introduced the concept of 
vascular spasm persisting after intestinal vas- 
cular occlusion [ 16, 191. Turner reported 
significantly reduced intestinal blood flow 
following relief of both mesenteric arterial 
and venous occlusions [23]. Vasoconstriction 
has also been postulated to play an important 
role in the pathogenesis of nonocclusive mes- 
enteric ischemia [l-3, 6, 14, 15, 16, 19, 241. 
Although controlled trials demonstrating im- 
proved survival of patients with acute mes- 
enteric ischemia treated with vasodilators are 
nonexistent, the adjunctive use of such agents 
appears theoretically sound. Clearly, the best 
vasodilator has not been determined, but 
intravenous glucagon appears to be a suitable 
agent for study in humans. 
The hemodynamic effects of glucagon, in 
pharmacologic doses, include positive inotro- 
pit and chronotropic actions as well as re- 
ductions in LVSW such as documented in 
the current study [9, 181. Glucagon increases 
celiac and superior mesenteric blood flow, as 
well as liver perfusion by increasing both 
portal venous and hepatic arterial blood flow 
[ 13, 181. The hormone significantly enhances 
intestinal villous tip blood flow, and effec- 
tively increases SMA blood flow despite SMA 
stenoses and digoxin-induced vasoconstriction 
[4, 171. Glucagon-induced reductions in in- 
testinal motility may theoretically lower the 
bowel’s energy requirements, and the accom- 
panying inhibition of gastric, biliary, and 
pancreatic secretion may be beneficial in 
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lessening the so called “enzymatic phase” of 
intestinal injury associated with vascular in- 
sufficiency [5, 151. 
Recently, we have shown that intrave- 
nously administered glucagon improves sur- 
vival in a rat model of acute mesenteric 
arterial insufficiency [lo]. It would seem that 
the adjunctive use of intravenous glucagon 
in pharmacologic doses deserves study in 
clinical instances of acute mesenteric isch- 
emia. This agent has been safely administered 
to humans [25]. The intravenous route of 
administration would allow rapid initiation 
of adjunctive therapy prior to obtaining con- 
firmatory angiography in patients suspected 
of having acute mesenteric ischemia, and 
theoretically would not mandate prolonged 
use of an indwelling arterial catheter. The 
results from this canine study suggest that 
intravenously administered glucagon is at 
least as effective as glucagon administered by 
a select intraarterial route in increasing mes- 
enter-k blood flow and reducing mesenteric 
vascular resistance. 
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